Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
‘Revolutionary’: James Island pharmacist weighs in on newly approved medication
A James Island pharmacist is looking to the future of pain management thanks to the Food and Drug Administration approving a new treatment.
BioPharma Dive21h
Vertex’s new pain drug gets first coverage nod from major insurer
Optum, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an ...